<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">akusherstvo</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics, Gynecology and Reproduction</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство, Гинекология и Репродукция</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7347</issn><issn pub-type="epub">2500-3194</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2313-7347/ob.gyn.rep.2024.454</article-id><article-id custom-type="elpub" pub-id-type="custom">akusherstvo-2051</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ОRIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group></article-categories><title-group><article-title>Prediction of hypertensive disorders in pregnant women in the «gray» risk zone following combined first-trimester screening</article-title><trans-title-group xml:lang="ru"><trans-title>Прогнозирование гипертензивных расстройств при беременности у пациенток в «серой» зоне риска по результатам комбинированного скрининга I триместра</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мостова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mostova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>620067; ул. Флотская, д. 52; Екатеринбург</p></bio><bio xml:lang="en"><p>Natal'ya V. Mostova</p><p>620067; 52 Flotskaya Str.; Ekaterinburg</p></bio><email xlink:type="simple">mostova-n24@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковалев</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovalev</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>620028;  ул. Репина, д. 3; Екатеринбург</p></bio><bio xml:lang="en"><p>Vladislav V. Kovalev</p><p>620028; 3 Repina Str.; Ekaterinburg</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кудрявцева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kudryavtseva</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>620067; ул. Флотская, д. 52;;  620028;  ул. Репина, д. 3; Екатеринбург</p></bio><bio xml:lang="en"><p>Elena V. Kudryavtseva</p><p>620067; 52 Flotskaya Str.; ; 620028; 3 Repina Str.; Ekaterinburg</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГАУЗ СО «Клинико-диагностический центр "Охрана здоровья матери и ребенка"»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Clinical Diagnostic Center "Maternal and Child Health Care"</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural State Medical University, Health Ministry of Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГАУЗ СО «Клинико-диагностический центр "Охрана здоровья матери и ребенка"»; ФГБОУ ВО «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Clinical Diagnostic Center "Maternal and Child Health Care"; Ural State Medical University, Health Ministry of Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>18</day><month>05</month><year>2024</year></pub-date><volume>18</volume><issue>2</issue><fpage>200</fpage><lpage>210</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Mostova N.V., Kovalev V.V., Kudryavtseva E.V., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Мостова Н.В., Ковалев В.В., Кудрявцева Е.В.</copyright-holder><copyright-holder xml:lang="en">Mostova N.V., Kovalev V.V., Kudryavtseva E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gynecology.su/jour/article/view/2051">https://www.gynecology.su/jour/article/view/2051</self-uri><abstract><sec><title>   Introduction</title><p>   Introduction. In obstetrics, hypertensive disorders of pregnancy (HDP) including preeclampsia (РЕ) are one of the primary causes resulting in critical cases and maternal mortality. HDP prediction is a milestone that allows preventing complications as well as reducing the number of most common relevant complications of pregnancy. Existing algorithms that predict PE risk distribute the risks in such a way that a considerable number of patients fall into the category of false negative results, and, consequently, receive no timely prevention and proper follow-up. In particular, this cohort usually consists of patients with borderline high risks, who may be designated as a medium risk group or located in a “gray” zone.</p></sec><sec><title>   Aim</title><p>   Aim: to develop a prognostic model for risk stratification in female patients with borderline to high developing PE risk based on combined first-trimester screening.</p></sec><sec><title>   Materials and Methods</title><p>   Materials and Methods. A prospective comparative study included 1089 female patients who underwent a combined screening at 11–14 weeks of gestation. Group 1 consisted of female patients at high РЕ risk (1:100 and greater), while female patients at moderate risk (1:101–1:250) and low risk (below 1:250) were included into Group 2 and Group 3, respectively. All pregnant women underwent examination including assessed anamnestic, general clinical and laboratory data, mean blood pressure (BP), uterine artery pulsatility index, serum level of human chorionic gonadotropin beta-subunits (β-hCG), placental growth factor (PlGF), pregnancy-associated plasma protein-A (PAPP-A).</p></sec><sec><title>   Results</title><p>   Results. An impact of various factors on risk of developing hypertensive disorders in pregnancy was assessed by binary logistic regression by identifying most significant among them and generating a statistical prediction model – the prognostic index of hypertensive disorders in pregnancy. The latter included: obstetric history, body mass index, PlGF, mean ВР, and alanine aminotransferase level. The sensitivity and specificity comprised 91.2 and 53.6 %, respectively, and the method effectivenesswas 81.8 %.</p></sec><sec><title>   Conclusion</title><p>   Conclusion. The method proposed for HDP prediction is a second-line approach that may be used in clinical practice to stratify patients with borderline high risk of developing PE.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>   Введение</title><p>   Введение. Гипертензивные расстройства при беременности (ГРБ), в том числе и преэклампсия (ПЭ), являются одной из первостепенных причин, приводящих к критическим ситуациям и материнской смертности в акушерстве. Прогнозирование данного состояния является основополагающим моментом, который лежит в основе профилактики осложнений, а также снижения количества наиболее частых акушерских осложнений, возникающих при реализации ГРБ. Существующие алгоритмы, прогнозирующие риск ПЭ, распределяют риски таким образом, что немалое количество пациенток попадают в категорию ложноотрицательных результатов, и, как следствие, не получают своевременную профилактику и соответствующее динамическое наблюдение. Это, как правило, категория пациенток, имеющих пограничные с высоким риски, которых можно обозначить, как группу среднего риска находящихся в «серой» зоне.</p></sec><sec><title>   Цель</title><p>   Цель: разработка прогностической модели для стратификации пациенток, имеющих пограничные с высоким риски развития ПЭ по результатам комбинированного скрининга I триместра.</p></sec><sec><title>   Материалы и методы</title><p>   Материалы и методы. В проспективное сравнительное исследование включены 1089 пациенток, прошедших комбинированный скрининг I триместра в сроке беременности 11–14 недель. В группу 1 вошли пациентки с высоким риском ПЭ (1:100 и выше), в группу 2 – со средним (1:101–1:250) и в группу 3 – с низким (ниже 1:250). Всем беременным проведено обследование, включавшее оценку анамнестических, общеклинических и лабораторных данных, измерение уровня среднего артериального давления (АД), пульсационного индекса маточных артерий, определение содержания в сыворотке крови бета-субъединицы хорионического гонадотропина человека (β-ХГЧ), плацентарного фактора роста (англ. placental growth factor, PlGF), ассоциированного с беременностью протеина-А плазмы (англ. pregnancy-associated plasma protein-A, РАРР-А).</p></sec><sec><title>   Результаты</title><p>   Результаты. Оценка влияния различных факторов на риск развития ГРБ осуществлялась методом бинарной логистической регрессии; были выявлены наиболее значимые из них и построена статистическая модель прогнозирования – прогностический индекс гипертензивных расстройств при беременности. Он включает в себя: акушерский анамнез; индекс массы тела; значения PlGF, среднего АД и аланинаминотрансферазы. Показатели чувствительности и специфичности составили 91,2 и 53,6 % соответственно, эффективность способа – 81,8 %.</p></sec><sec><title>   Заключение</title><p>   Заключение. Предложенный способ прогнозирования ГРБ является тестом второй линии и может быть использован в клинической практике для стратификации пациенток, имеющих пограничные с высоким риски развития ПЭ.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>преэклампсия</kwd><kwd>ПЭ</kwd><kwd>гипертензивные расстройства при беременности</kwd><kwd>ГРБ</kwd><kwd>гестационная гипертензия</kwd><kwd>большие акушерские синдромы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>preeclampsia</kwd><kwd>PE</kwd><kwd>hypertensive disorders in pregnancy</kwd><kwd>HDP</kwd><kwd>gestational hypertension</kwd><kwd>great obstetrics syndromes</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Авторы заявляют об отсутствии финансовой поддержки</funding-statement><funding-statement xml:lang="en">The authors declare no funding</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–7. doi: 10.1053/j.semperi.2009.02.010.</mixed-citation><mixed-citation xml:lang="en">Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–7. doi: 10.1053/j.semperi.2009.02.010.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Trends in maternal mortality 2000 to 2020: estimates by WHO, UNICEF, UNFPA, World Bank Group and UNDESA/Population Division, Overview 2023. World Health Organization, 2023. Режим доступа: www.who.int/publications/i/item/9789240068759. [Дата обращения: 02. 10. 2023].</mixed-citation><mixed-citation xml:lang="en">Trends in maternal mortality 2000 to 2020: estimates by WHO, UNICEF, UNFPA, World Bank Group and UNDESA/Population Division, Overview 2023. World Health Organization, 2023. Available at: www.who.int/publications/i/item/9789240068759. [Accessed: 02. 10. 2023].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Сидорова И.С., Никитина Н.А., Филиппов О.С. и др. Решенные и нерешенные вопросы преэклампсии по результатам анализа материнской смертности за последние 10 лет. Акушерство и гинекология. 2021;(4):64–74. doi: 10.18565/aig.2021.4.64-74.</mixed-citation><mixed-citation xml:lang="en">Sidorova I.S., Nikitina N.A., Filippov O.S. et al. Current issues in preeclampsia: a ten-year analysis of maternal mortality. [Reshennye i nereshennye voprosy preeklampsii po rezul'tatam analiza materinskoj smertnosti za poslednie 10 let]. Akusherstvo i ginekologiya. 2021;4:64–74. (In Russ.). doi: 10.18565/aig.2021.4.64-74.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Than N.G., Romero R., Tarca A.L. et al. Integrated systems biology approach identifies novel maternal and placental pathways of preeclampsia. Front Immunol. 2018;9:1661. doi: 10.3389/fimmu.2018.01661.</mixed-citation><mixed-citation xml:lang="en">Than N.G., Romero R., Tarca A.L. et al. Integrated systems biology approach identifies novel maternal and placental pathways of preeclampsia. Front Immunol. 2018;9:1661. doi: 10.3389/fimmu.2018.01661.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Romero R. Prenatal medicine: the child is the father of the man. 1996. J Matern Fetal Neonatal Med. 2009;22(8):636–9. doi: 10.1080/14767050902784171.</mixed-citation><mixed-citation xml:lang="en">Romero R. Prenatal medicine: the child is the father of the man. 1996. J Matern Fetal Neonatal Med. 2009;22(8):636–9. doi: 10.1080/14767050902784171.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kessous R., Shoham-Vardi I., Pariente G. et al. Long-term maternal atherosclerotic morbidity in women with pre-eclampsia. Heart. 2015;101(6):442–6. doi: 10.1136/heartjnl-2014-306571.</mixed-citation><mixed-citation xml:lang="en">Kessous R., Shoham-Vardi I., Pariente G. et al. Long-term maternal atherosclerotic morbidity in women with pre-eclampsia. Heart. 2015;101(6):442–6. doi: 10.1136/heartjnl-2014-306571.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Brouwers L., van der Meiden-van Roest A.J., Savelkoul C. et al. Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease : a systematic review and meta-analysis. BJOG. 2018;125(13):1642–54. doi: 10.1111/1471-0528.15394.</mixed-citation><mixed-citation xml:lang="en">Brouwers L., van der Meiden-van Roest A.J., Savelkoul C. et al. Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease : a systematic review and meta-analysis. BJOG. 2018;125(13):1642–54. doi: 10.1111/1471-0528.15394.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sukmanee J., Liabsuetrakul T. Risk of future cardiovascular diseases in different years postpartum after hypertensive disorders of pregnancy : а systematic review and meta-analysis. Medicine. 2022;101(30):e29646. doi: 10.1097/MD.0000000000029646.</mixed-citation><mixed-citation xml:lang="en">Sukmanee J., Liabsuetrakul T. Risk of future cardiovascular diseases in different years postpartum after hypertensive disorders of pregnancy : а systematic review and meta-analysis. Medicine. 2022;101(30):e29646. doi: 10.1097/MD.0000000000029646.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Долгополова Е.Л., Ломова Н.А., Караваева А.Л. и др. Тяжелая преэклампсия и задержка роста плода: отдаленные прогнозы для матерей и потомства. Акушерство и гинекология. 2020;(12):100–7. doi: 10.18565/aig.2020.12.100-107.</mixed-citation><mixed-citation xml:lang="en">Dolgopolova E.L., Lomova N.A., Karavaeva A.L. et al. Severe pre-eclampsia and fetal growth restriction: long-term projections for mother and offspring. [Tyazhelaya preeklampsiya i zaderzhka rosta ploda: otdalennye prognozy dlya materej i potomstva]. Akusherstvo i ginekologiya. 2020;(12):100–7. (In Russ.). doi: 10.18565/aig.2020.12.100-107.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Yan S., Lyu J., Liu Z. et al. Association of gestational hypertension and preeclampsia with offspring adiposity : a systematic review and meta-analysis. Front Endocrinol. 2022;13:906781. doi: 10.3389/fendo.2022.906781.</mixed-citation><mixed-citation xml:lang="en">Yan S., Lyu J., Liu Z. et al. Association of gestational hypertension and preeclampsia with offspring adiposity : a systematic review and meta-analysis. Front Endocrinol. 2022;13:906781. doi: 10.3389/fendo.2022.906781.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C., Li J., Qin G. et al. Maternal hypertensive disorder of pregnancy and offspring early-onset cardiovascular disease in childhood, adolescence, and young adulthood: a national population-based cohort study. PLoS Med. 2021;18(9):e1003805. doi: 10.1371/journal.pmed.1003805.</mixed-citation><mixed-citation xml:lang="en">Huang C., Li J., Qin G. et al. Maternal hypertensive disorder of pregnancy and offspring early-onset cardiovascular disease in childhood, adolescence, and young adulthood: a national population-based cohort study. PLoS Med. 2021;18(9):e1003805. doi: 10.1371/journal.pmed.1003805.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Karatza A.A., Dimitriou G. Preeclampsia emerging as a novel risk factor for cardiovascular disease in the offspring. Curr Pediatr Rev. 2020;16(3):194–9. doi: 10.2174/1573396316666191224092405.</mixed-citation><mixed-citation xml:lang="en">Karatza A.A., Dimitriou G. Preeclampsia emerging as a novel risk factor for cardiovascular disease in the offspring. Curr Pediatr Rev. 2020;16(3):194–9. doi: 10.2174/1573396316666191224092405.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">NICE Clinical Guideline. Hypertension in pregnancy: diagnosis and management. National Institute for Health and Care Excellence (NICE), 2023. 62 p. Режим доступа: https://www.nice.org.uk/guidance/ng133/resources/hypertension-in-pregnancy-diagnosis-and-management-pdf-66141717671365. [Дата обращения: 02. 10. 2023].</mixed-citation><mixed-citation xml:lang="en">NICE Clinical Guideline. Hypertension in pregnancy: diagnosis and management. National Institute for Health and Care Excellence (NICE), 2023. 62 p. Available at: https://www.nice.org.uk/guidance/ng133/resources/hypertension-in-pregnancy-diagnosis-and-management-pdf-66141717671365. [Accessed: 02. 10. 2023].</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">AGOG practice advisory: low-dose aspirin use for the prevention of preeclampsia and related morbidity and mortality. AGOG, 2021. Режим доступа: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/12/low-dose-aspirin-use-for-the-prevention-of-preeclampsia-and-related-morbidity-and-mortality. [Дата обращения: 02. 10. 2023].</mixed-citation><mixed-citation xml:lang="en">AGOG practice advisory: low-dose aspirin use for the prevention of preeclampsia and related morbidity and mortality. AGOG, 2021. Available at: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/12/low-dose-aspirin-use-for-the-prevention-of-preeclampsia-and-related-morbidity-and-mortality. [Accessed: 02. 10. 2023].</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Poon L.C., Kametas N.A., Maiz N. et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53(5):812–8. doi: 10.1161/HYPERTENSIONAHA.108.127977.</mixed-citation><mixed-citation xml:lang="en">Poon L.C., Kametas N.A., Maiz N. et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53(5):812–8. doi: 10.1161/HYPERTENSIONAHA.108.127977.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">O'Gorman N., Wright D., Poon L.C. et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49(6):756–60. doi: 10.1002/uog.17455.</mixed-citation><mixed-citation xml:lang="en">O'Gorman N., Wright D., Poon L.C. et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49(6):756–60. doi: 10.1002/uog.17455.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Poon L.C., Stratieva V., Piras S. et al. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat Diagn. 2010;30(3):216–23. doi: 10.1002/pd.2440.</mixed-citation><mixed-citation xml:lang="en">Poon L.C., Stratieva V., Piras S. et al. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Prenat Diagn. 2010;30(3):216–23. doi: 10.1002/pd.2440.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wright D., Akolekar R., Syngelaki A. et al. A competing risks model in early screening for preeclampsia. Fetal Diagn Ther. 2012;32(3):171–8. doi: 10.1159/000338470.</mixed-citation><mixed-citation xml:lang="en">Wright D., Akolekar R., Syngelaki A. et al. A competing risks model in early screening for preeclampsia. Fetal Diagn Ther. 2012;32(3):171–8. doi: 10.1159/000338470.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tan M.Y., Wright D., Syngelaki A. et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018;51(6):743–50. doi: 10.1002/uog.19039.</mixed-citation><mixed-citation xml:lang="en">Tan M.Y., Wright D., Syngelaki A. et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018;51(6):743–50. doi: 10.1002/uog.19039.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Poon L.C., Shennan A., Hyett J.A. et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145 Suppl 1(Suppl 1):1–33. doi: 10.1002/ijgo.12802.</mixed-citation><mixed-citation xml:lang="en">Poon L.C., Shennan A., Hyett J.A. et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145 Suppl 1(Suppl 1):1–33. doi: 10.1002/ijgo.12802.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Приказ Минздрава России от 20. 10. 2020 N 1130н «Об утверждении Порядка оказания медицинской помощи по профилю "акушерство и гинекология"». М.: Министерство здравоохранения Российской Федерации, 2020. 688 с. Режим доступа: http://perinatcentr.ru/files/N_1130.pdf. [Дата обращения: 02. 10. 2023].</mixed-citation><mixed-citation xml:lang="en">Order of the Ministry of Health of Russia dated of October 20, 2020 No. 1130n "On approval of the Procedure for providing medical care in the field of obstetrics and gynecology". [Prikaz Minzdrava Rossii ot 20. 10. 2020 № 1130n «Ob utverzhdenii Poryadka okazaniya medicinskoj pomoshchi po profilyu "akusherstvo i ginekologiya"»]. Moscow: Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2020. 688 с. (In Russ.). Available at: http://perinatcentr.ru/files/N_1130.pdf. [Accessed: 02. 10. 2023].</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Rolnik D.L., Wright D., Poon L.C. et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50(4):492–5. doi: 10.1002/uog.18816.</mixed-citation><mixed-citation xml:lang="en">Rolnik D.L., Wright D., Poon L.C. et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50(4):492–5. doi: 10.1002/uog.18816.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Wright D., Poon L.C., Rolnik D.L. et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol. 2017;217(6):685.e1–685.e5. doi: 10.1016/j.ajog.2017.08.110.</mixed-citation><mixed-citation xml:lang="en">Wright D., Poon L.C., Rolnik D.L. et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol. 2017;217(6):685.e1–685.e5. doi: 10.1016/j.ajog.2017.08.110.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Кудрявцева Е.В., Канивец И.В., Киевская Ю.К. и др. Неинвазивный пренатальный тест в России: популяционное исследование. Акушерство и гинекология. 2019;(12):28–33. doi: 10.18565/aig.2019.12.30-35.</mixed-citation><mixed-citation xml:lang="en">Kudryavtseva E.V., Kanivets I.V., Kievskaya Yu.K. et al. Noninvasive prenatal testing in Russia: a population study. [Neinvazivnyj prenatal'nyj test v Rossii: populyacionnoe issledovanie]. Akusherstvo i ginekologiya. 2019;(12):28–33. (In Russ.). doi: 10.18565/aig.2019.12.30-35.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Кудрявцева Е.В., Ковалев В.В., Николаева Е.Б., Дектярев А.А. Неинвазивный пренатальный скрининг: первый опыт Свердловской области. Уральский медицинский журнал. 2019;15(183):78–81. URL: https://www.elibrary.ru/item.asp?id=41589641&amp;ysclid=lwbzesv5a2697312447.</mixed-citation><mixed-citation xml:lang="en">Kudryavtseva E.V., Kovalev V.V., Nikolaeva E.B., Dektyarev A.A. Non-invasive prenatal screening: first experience of Sverdlovsk region. [Neinvazivnyj prenatal'nyj skrining: pervyj opyt Sverdlovskoj oblasti]. Ural'skij medicinskij zhurnal. 2019;15(183):78–81. (In Russ.). URL: https://www.elibrary.ru/item.asp?id=41589641&amp;ysclid=lwbzesv5a2697312447.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Morain S., Greene M.F., Mello M.M. A new era in noninvasive prenatal testing. N Engl J Med. 2013;369(6):499–501. doi: 10.1056/NEJMp1304843.</mixed-citation><mixed-citation xml:lang="en">Morain S., Greene M.F., Mello M.M. A new era in noninvasive prenatal testing. N Engl J Med. 2013;369(6):499–501. doi: 10.1056/NEJMp1304843.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Холин А.М., Муминова К.Т., Балашов И.С. и др. Прогнозирование преэклампсии в первом триместре беременности: валидация алгоритмов скрининга на российской популяции. Акушерство и гинекология. 2017;(8):74–84. doi: 10.18565/aig.2017.8.74-84.</mixed-citation><mixed-citation xml:lang="en">Kholin A.M., Muminova K.T., Balashov I.S. et al. First-trimester prediction of preeclampsia: Validation of screening algorithms in a Russian population. [Prognozirovanie preeklampsii v pervom trimestre beremennosti: validaciya algoritmov skrininga na rossijskoj populyacii]. Akusherstvo i ginekologiya. 2017;(8):74–84. (In Russ.). doi: 10.18565/aig.2017.8.74-84.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Parra-Cordero M., Rodrigo R., Barja P. et al. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol. 2013;41(5):538–44. doi: 10.1002/uog.12264.</mixed-citation><mixed-citation xml:lang="en">Parra-Cordero M., Rodrigo R., Barja P. et al. Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. Ultrasound Obstet Gynecol. 2013;41(5):538–44. doi: 10.1002/uog.12264.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
